Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

(2016) F L Scott et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects

(2016) Eric Legangneux et al.   CLINICAL THERAPEUTICS

Ozanimod: a better or just another S1P receptor modulator?

(2016) Per Soelberg Sørensen   LANCET NEUROLOGY

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

(2016) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells and endothelium and modulated during inflammatory bowel disease

(2016) T Karuppuchamy et al.   Mucosal Immunology

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis

(2015) Adnan M. Subei et al.   CNS DRUGS

Effect of Ponesimod, a Selective S1P1Receptor Modulator, on the QT Interval in Healthy Individuals

(2014) Matthias Hoch et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1receptor modulator: Favorable impact of dose up-titration

(2014) P. Brossard et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study

(2013) Patrick Brossard et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy

(2013) G Francis et al.   Multiple Sclerosis Journal

Use of immunomodulators and biologic therapies in children with inflammatory bowel disease

(2010) Athos Bousvaros   Expert Review of Clinical Immunology

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

(2009) Alessandra Lugaresi   Expert Opinion on Drug Delivery

Definition of Phenotypic Characteristics of Childhood-Onset Inflammatory Bowel Disease

(2008) Johan Van Limbergen et al.   GASTROENTEROLOGY

Therapeutic strategies for the management of ulcerative colitis

(2008) Siew C. Ng et al.   INFLAMMATORY BOWEL DISEASES